Currently, an rAAV vector called 4D-710 is being evaluated in a Phase 1/2 trial in CF patients with bi-allelic CFTR mutations or a single mutation who are ineligible or intolerant of available HEMT. The gene discussed is CFTR; the disease is cystic fibrosis.